TIDMAPH

RNS Number : 1386W

Alliance Pharma PLC

17 August 2015

 
 For immediate release                                                         17 August 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Interim Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2015 on Wednesday 9 September 2015.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

 
 Alliance Pharma plc             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
 
                                 + 44 (0) 20 7466 
 Buchanan                         5000 
 Mark Court / Sophie Cowles 
  / Jane Glover 
 
                                 + 44 (0) 20 7260 
 Numis Securities Limited         1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: David 
  Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORPIMJTMBJBBMA

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.